RxDoctor Payments Data

Anne Brockman, MD

Family Medicine · Evergreen, CONPI 1962455329

Payments from drug & device makers

$431in general payments, 2019–2025

Across 16 payments — averaging $26.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$127
  • Pfizer$110
  • Amgen$79
  • GSK$37
  • Merck$34
  • Inogen, Inc.$29
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Edwards Lifesciences1$127
Pfizer5$110
Amgen4$79
GSK2$37
Merck2$34
Inogen, Inc.1$29
Sanofi Pasteur Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$431 in reported general payments places this provider in the 70th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$57,743
Medicare patients
284
Services billed
905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$88,709
JardianceEmpagliflozin15$21,749
XareltoRivaroxaban12$18,841
SymbicortBudesonide/Formoterol Fumarate23$7,278
Qvar RedihalerBeclomethasone Dipropionate13$3,907
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,586
PaxlovidNirmatrelvir/Ritonavir18$2,577
Albuterol Sulfate HfaAlbuterol Sulfate79$2,257
Levothyroxine Sodium226$2,226
Estradiol17$2,179
Atorvastatin Calcium175$1,547
Gabapentin97$1,303
Escitalopram Oxalate69$1,275
Rosuvastatin Calcium65$1,144
Metoprolol Succinate83$1,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$110$91,28698 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Evergreen

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →